Latest Breaking News On - Helmsley trust professor - Page 1 : vimarsana.com

FARAPULSE s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation News provided by Share this article Share this article Pioneering technology has demonstrated potential to improve safety for patients with paroxysmal atrial fibrillation and simplify procedures for physicians MENLO PARK, Calif., March 3, 2021 /PRNewswire/ - FARAPULSE Inc. today announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal Atrial Fibrillation (AF). AF is a heart rhythm disorder that affects nearly 6 million Americans and makes them five times more likely to have a stroke than individuals with a regular heartbeat. The first patients were treated at New York s Mount Sinai Hospital by Dr. Vivek Reddy, the Hel

United statesAllan zingelerVivek reddyIcahn school of medicine at mount sinaiJournal of the american college cardiologyDrug administrationMount sinai health systemHelmsley trust professor of medicineInvestigational device exemptionPulsed field ablationAtrial fibrillationNew yorkMount sinai hospitalHelmsley trust professorIcahn schoolMount sinai